The inhibition of BCR–ABL1 by the tyrosine kinase inhibitor imatinib led to dramatically improved molecular responses and survival of CML patients (Roy et al. 2006). This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.